English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/34425
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMartínez-Alonso, Carlos-
dc.contributor.authorMellado, Mario-
dc.contributor.authorRodríguez Frade, José M.-
dc.date.accessioned2011-04-08T07:34:22Z-
dc.date.available2011-04-08T07:34:22Z-
dc.date.issued2005-10-06-
dc.identifier.citationUS 2005221287 (A1)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/34425-
dc.descriptionFecha de presentación internacional: 31.12.2002. - Titulares: Consejo Superior de Investigaciones Científicas (CSIC). - Científicas Pharmacia Spain, S.A.es_ES
dc.description.abstractA method is provided of identifying compounds for use in a pharmaceutical composition having an anti-viral effect against CXCR4-dependent HIV activity comprising: providing a first aliquot of CXCR-4-expressing GH-Tg cells; contacting said first aliquot with HIV particles; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with a test ligand; contacting said second aliquot with HIV particles; and isolating virus from said first and said second aliquot of cells, wherein a decrease in the ability to isolate virus from said second aliquot cells indicates said test ligand possess anti-viral activity against HIV. Also provided is a method of identifying compounds for use in a pharmaceutical composition having a therapeutic effect against a disease involving CXCR4-dependent chemotaxis comprising providing a first aliquot CXCR4-expressing GH-Tg cells; contacting said first aliquot with CXCL12; measuring a first migration indes; providing a second aliquot of CXCR4-expressing GH-Tg cells; contacting said second aliquot with CXCL12; contacting said second aliquot with a test ligand; measuring a second migration index; and determing a therapeutic potential. In addition, compounds for us in a pharmaceutical composition having a therapeutic effect against a SOCS3 inhibitable disease are identified by a method comprising: providing a first cell having at least one chemokine receptor expressed thereon, said first cell having been transfected with at least one SOCS construct; contacting said first cell with at least one chemokine, measuring a first migration index; providing a second cell having at least one chemokine receptor expressed thereon, said second cell having been transfected with at least one SOCS construct; contacting said second cell with at least one chemokine; measuring a second migration index; and determining a therapeutic potential subjects having a disease associated with CXCR4-dependent HIV are treated by administering to said subject a therapeutically anti-viral effective amount of a compound that induces the expression of SOCS3 and a pharmaceutically acceptable carrier.es_ES
dc.language.isoenges_ES
dc.rightsopenAccesses_ES
dc.titleFunctional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulationes_ES
dc.typepatentees_ES
dc.description.peerreviewedPeer reviewedes_ES
Appears in Collections:(CNB) Patentes
Files in This Item:
File Description SizeFormat 
US2005221287A1.pdf1,85 MBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.